Despite the success of antitumor necrosis factor (TNF) therapy in Crohn's disease, there remains a need for biologic therapy that targets other immune pathways of disease. Ustekinumab is a fully human monoclonal immunoglobulin antibody that targets the interleukin (IL)-12 and IL-23 shared P40 subunit. It has been studied in 2 phase 2 randomized, double-blind, placebo-controlled trials in Crohn's disease. This article reviews the clinical efficacy and safety data of ustekinumab in Crohn's disease in anticipation of the final results of the phase III development program in moderate to severe Crohn's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gtc.2014.05.013 | DOI Listing |
Publication Analysis
Top Keywords
crohn's disease
20
disease
6
crohn's
5
update ustekinumab
4
ustekinumab treatment
4
treatment crohn's
4
disease despite
4
despite success
4
success antitumor
4
antitumor necrosis
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!